Enduring Material

• Understanding of how current psoriasis categorization can affect treatment
• Understanding the proposed new recategorization of psoriasis severity

PsoundBytes CME- It’s Time for a Change: IPC Psoriasis Severity Reclassification

• Andrew Blauvelt, MD, MBA - Oregon Medical Research Center
• Bruce Strober, MD

• The National Psoriasis Foundation designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The National Psoriasis Foundation designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Psoriasis classification is more than a BSA or PASI score. Listen as Dr. Bruce Strober, Clinical Professor of Dermatology at Yale University, New Haven, CT and Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR discuss the International Psoriasis Council’s rationale for changing psoriasis severity classification for treatment decisions and clinical trials.

NPF Staff/Planning Committee, has disclosed no relevant financial relationships with commercial interests.

Andrew Blauvelt, MD, MBA has disclosed a relevant financial relationship with a commercial interest in the last 12 months:

• Abbvie - Speaking
• Aclaris, Almirall, Avena, Athenex, Boehringer, Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly & Company, Forte Galderma, Incyte, Janssen, Leo, Novartis, Ortho, Pfizer, Rapt, Regeron, Sandoz, Sanofi, Genzyme, SunPharma & UCB Pharma - Scientific advisor &/or clinical study investigator

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol-Myers-Squibb, Connect Biopharma, Dermavant, Equillium, Janssen, Leo, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithK - Consulting - Relationship Has Not Ended
• AbbVie, Eli Lilly, Janssen, Sanofi-Genzyme - Speaking - Relationship Has Not Ended
• CorEvitas (formerly Corrona) Psoriasis Registry - Co-Scientific Director - Relationship Has Not Ended
• Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira, Cara, Novartis - Investigator - Relationship Has Not Ended
• Connect Biopharma - Shareholder - Relationship Has Not Ended
• Journal of Psoriasis and Psoriatic Arthritis - Editor-in-Chief - Relationship Has Not Ended

Support for this activity is gratefully acknowledged from BMS. Support for this activity is gratefully acknowledged from Eli Lilly & Company. Support for this activity is gratefully acknowledged from Novartis. Support for this activity is gratefully acknowledged from Ortho.

• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

100 %

6/9/2021